Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Clin Transl Oncol. 2012 Jul;14(7):536-40. doi: 10.1007/s12094-012-0837-8.
Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours originating in the digestive tract. These tumours have become a model of multidisciplinary work in oncology: the participation of several specialities (oncologists, pathologists, surgeons, molecular biologists, radiologists and others) has allowed advances in the understanding of this tumour and the consolidation of a targeted therapy, imatinib, as the first molecular treatment that is efficacious in solid tumours. Following the introduction of this drug, median survival of patients with advanced stage GIST has gone from 18 to more than 60 months. Therapy planning of GIST must be considered within a multidisciplinary context, and it is advisable that it takes place in reference centres for the care of sarcomas and GIST participating in clinical trials.
胃肠道间质瘤（GIST）是最常见的起源于消化道的间叶组织肿瘤。这些肿瘤已经成为肿瘤学多学科工作的典范：多个专业（肿瘤学家、病理学家、外科医生、分子生物学家、放射科医生等）的参与使人们对这种肿瘤有了更深入的了解，并巩固了一种靶向治疗药物伊马替尼，使其成为治疗实体瘤有效的第一种分子治疗药物。这种药物问世后，晚期 GIST 患者的中位生存期从 18 个月延长至 60 个月以上。GIST 的治疗方案必须在多学科背景下考虑，最好在参与临床试验的肉瘤和 GIST 治疗中心进行。
